피부 경유 패치 (Transdermal Patches) 시장조사 보고서

Report Overview

The global transdermal patches market is projected to reach 8.0 USD Billion by 2029 from USD 6.2 Billion in 2023, at a CAGR of 4.5% from 2023 to 2029. The factors driving the growth of the global transdermal patches market include the rising prevalence of chronic diseases, the expanding use of analgesic patches, technological advancements in transdermal patches, and the shift from traditional injections to transdermal patches. Nonetheless, during the anticipated period, factors such as drug failures, recalls of transdermal drug delivery systems, and increasing healthcare facility expenses will probably constrain market expansion to some degree.

“The matrix patches segment is expected to grow with the highest CAGR in patch type of the transdermal patches market.”
Due to a number of characteristics that increase the patch’s appeal and efficacy, the matrix patches segment is expected to grow at the highest CAGR in the transdermal patch market. In matrix patches, the medicine is evenly dispersed within a polymer matrix, providing a straightforward but effective design. This design promotes the best possible drug absorption via the skin by enabling a prolonged, regulated release of the medicinal substance. Due to its adaptability, matrix patches are widely used in a variety of therapeutic fields. This is because they may be used to administer a broad range of drugs. Patient compliance and matrix patch efficacy are increasing as a result of ongoing technological improvements in matrix patch formulation and manufacturing.

“The silicone adhesives segment is expected to grow with the highest CAGR in the adhesive type of the transdermal patches market.”
Since silicone adhesives have particular advantages over other adhesives, it is expected that the silicone adhesive patches segment of the transdermal patch market will grow at the fastest CAGR. Silicone adhesives ensure patient comfort and adherence by forming a thin yet strong connection with the skin. Because they are biocompatible and hypoallergenic, they can be used by a wide range of patients with less chance of skin sensitivity or irritation. Silicone adhesive patches’ conformability and flexibility make them more comfortable to wear and encourage prolonged and regular use.

“Based on the Application Type, the pain management segment is expected to grow by the highest CAGR in the transdermal patches market.”
The market for transdermal patches is expected to grow at the fastest rate in the pain management segment due to the growing need for safe, non-invasive pain reduction options. Pain-relieving transdermal patches deliver an even and steady therapeutic impact by releasing analgesic drugs through the skin in a targeted and regulated manner. This method offers an alternative to invasive therapies and conventional oral drugs, making it especially tempting to people with chronic pain disorders.

“Based on the Distribution Channel, The online Pharmacies segment is expected to grow with the highest CAGR in the transdermal patches market.”
As a distribution channel for transdermal patches, the online pharmacies segment is anticipated to grow at the fastest rate in the market. This is due to the general trend of digitalization and the growing dependence of healthcare items on e-commerce platforms. Customers can get transdermal patches easily and conveniently from the comfort of their homes with the help of online pharmacies. The increasing popularity of e-commerce, together with its convenient ordering and doorstep delivery features, corresponds with the changing needs of patients who want hassle-free access to healthcare.

“Based on the End User, The Homecare Settings segment is expected to grow with the highest CAGR in the transdermal patches market.”
Given the growing trend towards patient-centered and personalized healthcare, the transdermal patch market’s homecare settings sector is expected to grow at the fastest rate as an end-user. For self-administration in domestic settings, transdermal patches are especially well-suited since they offer a convenient and non-invasive way to administer medication. The need for accessible, long-term treatment alternatives is fueled by the aging population and the rise of chronic illnesses. Transdermal patches are a perfect fit with this new paradigm in healthcare since homecare settings provide people the freedom to take care of their healthcare needs on their own.

“Asia Pacific to grow with the highest CAGR in the transdermal patches market during the forecast period.”
The transdermal patch market in Asia Pacific is expected to grow at the highest CAGR due to an array of factors that highlight the region’s changing healthcare landscape. Transdermal patches are becoming more and more popular due to the rising incidence of chronic illnesses and rising knowledge of non-invasive medication delivery techniques. The huge and aging population in the area is a major factor in the rising cost of healthcare, which in turn is driving up demand for accessible and patient-friendly treatment choices. The transdermal patch market in Asia Pacific is also expected to rise as a result of breakthroughs in pharmaceutical research and development, rising disposable incomes, and improved healthcare infrastructure.

A breakdown of the primary participants (supply-side) for the transdermal patches market referred to for this report is provided below:
• By Company Type: Tier 1–45%, Tier 2–30%, and Tier 3–25%
• By Designation: C-level–42%, Director Level–29%, and Others–29%
• By Region: North America–30%, Europe–25%, Asia Pacific–30%, Latin America- 10%, Middle East & Africa-5%

The prominent players in the transdermal patches market include Johnson & Johnson (U.S.), Viatris Inc. (U.S.), Hisamatsu Pharmaceuticals Co. Ltd. (Japan), Cipla Inc. (India), Teva Pharmaceutical Industries Ltd. (Israel), Agile Therapeutics (U.S.), Bayer AG (Germany), Luye Pharma Group (China), Sparsha Pharma International Pvt Ltd (India), Iontopatch (U.S.), Medherant Limited (U.K.), AdhexPharma (France), Evernow (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Alvogen Group Inc. (U.S.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), Nitto Denko Corporation (Japan), USB S.A. (Belgium), Boehringer Ingelheim International GmbH (Germany), Endo International plc. (Ireland),  LEAD CHEMICAL Co., Ltd. (Japan), Purdue Pharma L.P (U.S.) and Mundipharma International (U.K.).

Research Coverage:
The market study covers the transdermal patches market across various segments. It aims to estimate the market size and the growth potential of this market across different segments by patch type, adhesive type, application, distribution type, end-user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall transdermal patches market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:
§ Analysis of key drivers (Increasing prevalence of chronic diseases, Growing adoption of analgesic patches, Technological advancements in transdermal patches, Switching from conventional needle injections to transdermal patches), restraints (High procedural cost of vascular surgeries and associated products, Drug failure and recalls of transdermal drug delivery systems, Rising cost of healthcare facilities), opportunities (Collaborations between pharmaceutical companies and drug delivery firms, Self-administration and home care drug delivery systems) and challenges (Technical barriers related to skin irritation and permeability, Lack of skilled professionals)
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global transdermal patches market. The report analyzes this market by patch type, adhesive type, application, distribution channel, end-user, and region.
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global transdermal patches market.
• Market Development: Comprehensive information on the lucrative emerging markets by patch type, adhesive type, application, distribution channel, end-user, and region.
• Market Diversification: Exhaustive information about new products and services, growing geographies, recent developments, and investments in the global transdermal patches market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product and service offerings, and capabilities of leading players in the global transdermal patches market.

Table of Contents

1            INTRODUCTION            26

1.1         STUDY OBJECTIVES      26

1.2         MARKET DEFINITION   27

1.3         MARKET SCOPE             27

1.3.1      INCLUSIONS AND EXCLUSIONS OF STUDY         27

1.3.2      MARKETS COVERED     28

1.3.3      YEARS CONSIDERED     28

1.4         CURRENCY        29

TABLE 1             STANDARD CURRENCY CONVERSION RATES    29

1.5         STAKEHOLDERS            29

1.6         RECESSION IMPACT      29

2            RESEARCH METHODOLOGY     30

2.1         RESEARCH DATA           30

FIGURE 1           RESEARCH DESIGN       30

2.1.1      SECONDARY DATA       31

2.1.1.1   Key data from secondary sources     32

2.1.2      PRIMARY DATA 33

FIGURE 2           PRIMARY SOURCES       33

2.1.2.1   Key data from primary sources         34

2.1.2.2   Key industry insights          34

FIGURE 3           BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 35

FIGURE 4           BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 35

FIGURE 5           BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION            36

2.2         MARKET SIZE ESTIMATION       36

FIGURE 6           SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS          37

FIGURE 7           REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON          37

FIGURE 8           SUPPLY-SIDE MARKET SIZE ESTIMATION: TRANSDERMAL PATCHES  MARKET (2022)        38

FIGURE 9           BOTTOM-UP APPROACH           39

FIGURE 10         TOP-DOWN APPROACH             39

FIGURE 11         CAGR PROJECTIONS FROM DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023–2029)           40

FIGURE 12         CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS   41

2.3         MARKET BREAKDOWN AND DATA TRIANGULATION    41

FIGURE 13         DATA TRIANGULATION METHODOLOGY         42

2.4         MARKET SHARE ESTIMATION   43

2.5         ASSUMPTIONS FOR STUDY       43

2.6         RESEARCH LIMITATIONS           43

2.6.1      SCOPE-RELATED LIMITATIONS             43

2.6.2      METHODOLOGY-RELATED LIMITATIONS         44

2.7         RISK ASSESSMENT         44

TABLE 2             RISK ASSESSMENT: TRANSDERMAL PATCHES MARKET 44

2.8         IMPACT OF RECESSION ON TRANSDERMAL PATCHES MARKET 45

3            EXECUTIVE SUMMARY 46

FIGURE 14         TRANSDERMAL PATCHES MARKET, BY PATCH TYPE,  2023 VS. 2029 (USD MILLION)     46

FIGURE 15         TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2023 VS. 2029 (USD MILLION)             47

FIGURE 16         TRANSDERMAL PATCHES MARKET, BY APPLICATION,  2023 VS. 2029 (USD MILLION)             47

FIGURE 17         TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2023 VS. 2029 (USD MILLION)          48

FIGURE 18         TRANSDERMAL PATCHES MARKET, BY END USER,  2023 VS. 2029 (USD MILLION)     49

FIGURE 19         GEOGRAPHICAL SNAPSHOT OF TRANSDERMAL PATCHES MARKET            50

4            PREMIUM INSIGHTS      51

4.1         TRANSDERMAL PATCHES MARKET OVERVIEW 51

FIGURE 20         RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET            51

4.2         ASIA PACIFIC: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE AND COUNTRY (2022)  52

FIGURE 21         DRUG-IN-ADHESIVE PATCHES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022          52

4.3         TRANSDERMAL PATCHES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES           53

FIGURE 22         CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD              53

4.4         TRANSDERMAL PATCHES MARKET, REGIONAL MIX, 2021−2029 53

FIGURE 23         NORTH AMERICA WILL CONTINUE TO DOMINATE TRANSDERMAL PATCHES MARKET DURING FORECAST PERIOD            53

4.5         TRANSDERMAL PATCHES MARKET: DEVELOPING VS.  DEVELOPED MARKETS          54

FIGURE 24         DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING  FORECAST PERIOD   54

5            MARKET OVERVIEW     55

5.1         INTRODUCTION            55

5.2         MARKET DYNAMICS     55

FIGURE 25         TRANSDERMAL PATCHES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    55

5.2.1      DRIVERS            56

5.2.1.1   Increasing prevalence of chronic diseases       56

5.2.1.2   Growing adoption of analgesic patches          56

5.2.1.3   Technological advancements in transdermal patches    56

5.2.1.4   Switching from conventional needle injections to transdermal patches     57

5.2.2      RESTRAINTS     57

5.2.2.1   High procedural cost of transdermal surgeries and associated products    57

5.2.2.2   Drug failure and recalls of transdermal drug delivery systems    57

5.2.2.3   Rising cost of healthcare facilities    58

5.2.3      OPPORTUNITIES           58

5.2.3.1   Collaborations between pharmaceutical companies and drug delivery firms              58

5.2.3.2   Self-administration and home care drug delivery systems           59

5.2.4      CHALLENGES   59

5.2.4.1   Technical barriers related to skin irritation and permeability     59

5.2.4.2   Lack of skilled professionals             60

5.3         TECHNOLOGY ANALYSIS           60

5.4         INDUSTRY TRENDS       60

5.4.1      ADVANCEMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMS              60

5.5         VALUE CHAIN ANALYSIS            61

FIGURE 26         TRANSDERMAL PATCHES MARKET: VALUE CHAIN ANALYSIS              61

5.6         SUPPLY CHAIN ANALYSIS          62

FIGURE 27         TRANSDERMAL PATCHES MARKET: SUPPLY CHAIN ANALYSIS              63

5.7         TRADE ANALYSIS          63

5.7.1      TRADE ANALYSIS FOR TRANSDERMAL PATCHES           63

TABLE 3             IMPORT AND EXPORT DATA FOR TRANSDERMAL PATCHES, BY COUNTRY, 2022        63

5.8         PORTER’S FIVE FORCES ANALYSIS         64

TABLE 4             TRANSDERMAL PATCHES MARKET: PORTER’S FIVE FORCES ANALYSIS          64

5.8.1      THREAT OF NEW ENTRANTS    64

5.8.2      THREAT OF SUBSTITUTES         64

5.8.3      BARGAINING POWER OF BUYERS           64

5.8.4      BARGAINING POWER OF SUPPLIERS     65

5.8.5      INTENSITY OF COMPETITIVE RIVALRY 65

5.9         TARIFF AND REGULATORY LANDSCAPE            65

5.9.1      REGULATORY ANALYSIS            65

5.9.1.1   North America     65

5.9.1.1.1 US         65

5.9.1.1.2 Canada  65

5.9.1.2   Europe  65

5.9.1.3   Asia Pacific          66

5.9.1.3.1 China     66

5.9.1.3.2 Japan     66

5.9.1.3.3 India      66

5.9.1.4   Latin America      66

5.9.1.4.1 Brazil     66

5.9.1.4.2 Mexico  66

5.9.1.5   Middle East         67

5.9.1.6   Africa    67

5.9.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          67

TABLE 5             NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND  OTHER ORGANIZATIONS      67

TABLE 6             EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68

TABLE 7             ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         68

TABLE 8             LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND  OTHER ORGANIZATIONS      68

TABLE 9             REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND  OTHER ORGANIZATIONS      69

5.10       PATENT ANALYSIS        69

5.10.1    PATENT PUBLICATION TRENDS FOR TRANSDERMAL PATCHES              69

FIGURE 28         PATENT PUBLICATION TRENDS (JANUARY 2015–DECEMBER 2022)    69

5.10.2    JURISDICTION ANALYSIS: TOP APPLICANTS FOR PATENTS IN TRANSDERMAL PATCHES MARKET       70

FIGURE 29         TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTES) FOR TRANSDERMAL PATCH PATENTS (JANUARY 2015–DECEMBER 2022)      70

FIGURE 30         TOP APPLICANT COUNTRIES/REGIONS FOR TRANSDERMAL PATCHES (JANUARY 2015–APRIL 2022)  71

5.11       PRICING ANALYSIS        71

TABLE 10           AVERAGE SELLING PRICE TRENDS OF KEY PLAYERS, BY APPLICATION  72

TABLE 11           REGIONAL PRICING ANALYSIS OF TRANSDERMAL PATCHES, 2023 (USD)        73

5.12       KEY CONFERENCES & EVENTS IN 2023–2024       74

TABLE 12           TRANSDERMAL PATCHES MARKET: DETAILED LIST OF CONFERENCES & EVENTS          74

5.13       KEY STAKEHOLDERS & BUYING CRITERIA          75

5.13.1    KEY STAKEHOLDERS IN BUYING PROCESS         75

FIGURE 31         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TRANSDERMAL PATCHES          75

TABLE 13           INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TRANSDERMAL PATCHES          75

5.13.2    BUYING CRITERIA         75

FIGURE 32         KEY BUYING CRITERIA FOR TRANSDERMAL PATCHES  75

TABLE 14           KEY BUYING CRITERIA FOR TRANSDERMAL PATCHES  76

5.14       ECOSYSTEM/MARKET MAP       76

FIGURE 33         TRANSDERMAL PATCHES MARKET: ECOSYSTEM/MARKET MAP      76

5.15       ADJACENT MARKET ANALYSIS 77

FIGURE 34         TRANSDERMAL PATCHES MARKET: ADJACENT MARKETS              77

5.16       TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS     77

FIGURE 35         TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS              78

5.17       UNMET NEEDS 78

6            TRANSDERMAL PATCHES MARKET, BY PATCH TYPE     79

6.1         INTRODUCTION            80

TABLE 15           TRANSDERMAL PATCHES MARKET, BY PATCH TYPE, 2021–2029 (USD MILLION) 80

6.2         DRUG-IN-ADHESIVE PATCHES 80

TABLE 16           DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION)          81

TABLE 17           DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY COUNTRY,  2021–2029 (USD MILLION) 81

6.2.1      SINGLE-LAYER DRUG-IN-ADHESIVE PATCHES  82

6.2.1.1   Used to deliver wide range of medications     82

TABLE 18           SINGLE-LAYER DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)         82

6.2.2      MULTI-LAYER DRUG-IN-ADHESIVE PATCHES   83

6.2.2.1   Enhanced drug release and reduced side effects to drive adoption            83

TABLE 19           MULTI-LAYER DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)         84

6.3         MATRIX PATCHES         85

6.3.1      TECHNOLOGICAL ADVANCEMENTS IN NEW MATRIX MATERIALS TO SUPPORT MARKET GROWTH    85

TABLE 20           MATRIX TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)          85

6.4         RESERVOIR MEMBRANE PATCHES         86

6.4.1      OFFER GREAT CONTROL OVER DRUG DELIVERY RATES            86

TABLE 21           RESERVOIR MEMBRANE TRANSDERMAL PATCHES MARKET, BY COUNTRY,  2021–2029 (USD MILLION)         86

6.5         MICRONEEDLE PATCHES          87

6.5.1      ABILITY TO DELIVER ACTIVE PHARMACEUTICAL INGREDIENTS TO BOOST ADOPTION        87

TABLE 22           MICRONEEDLE TRANSDERMAL PATCHES MARKET, BY COUNTRY,  2021–2029 (USD MILLION) 87

6.6         IONTOPHORESIS PATCHES       88

6.6.1      USED TO DELIVER MEDICINES WITH LOW MOLECULAR WEIGHT              88

TABLE 23           IONTOPHORESIS TRANSDERMAL PATCHES MARKET, BY COUNTRY,  2021–2029 (USD MILLION) 88

6.7         VAPOR PATCHES           89

6.7.1      RELEASE ESSENTIAL OILS FOR UP TO 6 HOURS 89

TABLE 24           VAPOR TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)          89

 

7            TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE             90

7.1         INTRODUCTION            91

TABLE 25           TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE, 2021–2029 (USD MILLION)     91

7.2         ACRYLIC ADHESIVES    91

7.2.1      HIGH DURABILITY TO BOOST DEMAND            91

TABLE 26           TRANSDERMAL PATCHES MARKET FOR ACRYLIC ADHESIVES, BY COUNTRY,  2021–2029 (USD MILLION)         92

7.3         SILICONE ADHESIVES   92

7.3.1      LOW PEEL ADHESION PROPERTY MAKES IT IDEAL FOR MEDICAL APPLICATIONS 92

TABLE 27           TRANSDERMAL PATCHES MARKET FOR SILICONE ADHESIVES, BY COUNTRY,  2021–2029 (USD MILLION)         93

7.4         HYDROGEL ADHESIVES             94

7.4.1      INCREASING DEMAND FOR TRANSDERMAL DRUG DELIVERY SYSTEMS TO DRIVE MARKET       94

TABLE 28           TRANSDERMAL PATCHES MARKET FOR HYDROGEL ADHESIVES, BY COUNTRY,  2021–2029 (USD MILLION) 94

7.5         OTHER ADHESIVES       95

TABLE 29           TRANSDERMAL PATCHES MARKET FOR OTHER ADHESIVES, BY COUNTRY,  2021–2029 (USD MILLION)         95

8            TRANSDERMAL PATCHES MARKET, BY APPLICATION   96

8.1         INTRODUCTION            97

TABLE 30           TRANSDERMAL PATCHES MARKET, BY APPLICATION, 2021–2029 (USD MILLION)     97

8.2         PAIN MANAGEMENT    97

8.2.1      HIGH BURDEN OF CHRONIC PAIN WORLDWIDE TO DRIVE MARKET              97

TABLE 31           TRANSDERMAL PATCHES AVAILABLE FOR PAIN MANAGEMENT 98

TABLE 32           TRANSDERMAL PATCHES MARKET FOR PAIN MANAGEMENT, BY COUNTRY,  2021–2029 (USD MILLION)         98

8.3         SMOKING CESSATION  99

8.3.1      CONTROLLED DRUG DELIVERY AND REDUCED SIDE EFFECTS TO SUPPORT MARKET GROWTH    99

TABLE 33           TRANSDERMAL PATCHES AVAILABLE FOR SMOKING CESSATION       99

TABLE 34          TRANSDERMAL PATCHES MARKET FOR SMOKING CESSATION, BY COUNTRY,  2021–2029 (USD MILLION)         100

8.4         HORMONE REPLACEMENT THERAPY   100

TABLE 35           TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY, BY TYPE, 2021–2029 (USD MILLION)  101

TABLE 36           TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY,  BY COUNTRY, 2021–2029 (USD MILLION)    101

8.4.1      TRANSDERMAL TESTOSTERONE THERAPY       102

8.4.1.1   Increased bone density, better muscle development, and reduced risk factors to support market growth       102

TABLE 37           TRANSDERMAL PATCHES AVAILABLE FOR TRANSDERMAL TESTOSTERONE THERAPY        102

TABLE 38           TRANSDERMAL PATCHES MARKET FOR TRANSDERMAL TESTOSTERONE THERAPY,  BY COUNTRY, 2021–2029 (USD MILLION)  102

8.4.2      TRANSDERMAL ESTROGEN THERAPY   103

8.4.2.1   Growing use of transdermal contraceptive patches to drive market          103

TABLE 39           TRANSDERMAL PATCHES AVAILABLE FOR TRANSDERMAL ESTROGEN THERAPY   103

TABLE 40           TRANSDERMAL PATCHES MARKET FOR TRANSDERMAL ESTROGEN THERAPY,  BY COUNTRY, 2021–2029 (USD MILLION)           104

8.5         CENTRAL NERVOUS SYSTEM DISORDERS          104

8.5.1      EASE OF USE, SIMPLE TREATMENT REGIMEN, AND CONTINUOUS DELIVERY OF DRUGS TO DRIVE ADOPTION      104

TABLE 41           TRANSDERMAL PATCHES AVAILABLE FOR CENTRAL NERVOUS SYSTEM DISORDERS 105

TABLE 42           TRANSDERMAL PATCHES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS,  BY COUNTRY, 2021–2029 (USD MILLION)             105

8.6         CARDIOVASCULAR DISEASES   106

8.6.1      AVAILABILITY OF ALTERNATIVE AND ADVANCED DRUG DELIVERY OPTIONS TO LIMIT MARKET GROWTH 106

TABLE 43           TRANSDERMAL PATCHES AVAILABLE FOR CARDIOVASCULAR DISEASES          106

TABLE 44           TRANSDERMAL PATCHES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)       107

8.7         OTHER APPLICATIONS 107

TABLE 45           TRANSDERMAL PATCHES AVAILABLE FOR OTHER APPLICATIONS 108

TABLE 46           TRANSDERMAL PATCHES MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2021–2029 (USD MILLION)        108

9            TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL              109

9.1         INTRODUCTION            110

TABLE 47           TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 110

9.2         HOSPITAL PHARMACIES            110

9.2.1      LARGEST DISTRIBUTION CHANNEL FOR TRANSDERMAL PATCHES              110

TABLE 48           TRANSDERMAL PATCHES MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY,  2021–2029 (USD MILLION)            111

9.3         RETAIL PHARMACIES   111

9.3.1      IMPROVING HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET              111

TABLE 49           TRANSDERMAL PATCHES MARKET FOR RETAIL PHARMACIES, BY COUNTRY,  2021–2029 (USD MILLION)         112

9.4         ONLINE PHARMACIES  112

9.4.1      FASTEST-GROWING SEGMENT DUE TO EASY ACCESSIBILITY TO MEDICATIONS 112

TABLE 50           TRANSDERMAL PATCHES MARKET FOR ONLINE PHARMACIES, BY COUNTRY,  2021–2029 (USD MILLION)         113

 

10          TRANSDERMAL PATCHES MARKET, BY END USER          114

10.1       INTRODUCTION            115

TABLE 51           TRANSDERMAL PATCHES MARKET, BY END USER, 2021–2029 (USD MILLION) 115

10.2       HOME CARE SETTINGS 115

10.2.1    RAPID GROWTH IN GERIATRIC POPULATION TO SUPPORT  MARKET GROWTH          115

TABLE 52           TRANSDERMAL PATCHES MARKET FOR HOME CARE SETTINGS, BY COUNTRY,  2021–2029 (USD MILLION)   116

10.3       HOSPITALS & CLINICS  117

10.3.1    INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET              117

TABLE 53          TRANSDERMAL PATCHES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY,  2021–2029 (USD MILLION)         118

11          TRANSDERMAL PATCHES MARKET, BY REGION             119

11.1       INTRODUCTION            120

TABLE 54           TRANSDERMAL PATCHES MARKET, BY REGION, 2021–2029 (USD MILLION) 120

11.2       NORTH AMERICA          121

11.2.1    IMPACT OF RECESSION ON NORTH AMERICAN TRANSDERMAL PATCHES MARKET        121

FIGURE 36         NORTH AMERICA: TRANSDERMAL PATCHES MARKET SNAPSHOT        122

TABLE 55           NORTH AMERICA: TRANSDERMAL PATCHES MARKET, BY COUNTRY,  2021–2029 (USD MILLION) 123

TABLE 56           NORTH AMERICA: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE,  2021–2029 (USD MILLION)          123

TABLE 57           NORTH AMERICA: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE, 2021–2029 (USD MILLION) 124

TABLE 58           NORTH AMERICA: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)     124

TABLE 59           NORTH AMERICA: TRANSDERMAL PATCHES MARKET, BY APPLICATION,  2021–2029 (USD MILLION)        125

TABLE 60           NORTH AMERICA: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY, BY TYPE, 2021–2029 (USD MILLION)              125

TABLE 61           NORTH AMERICA: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 126

TABLE 62           NORTH AMERICA: TRANSDERMAL PATCHES MARKET, BY END USER,  2021–2029 (USD MILLION)          126

11.2.2    US         126

11.2.2.1 Largest market for transdermal patches         126

TABLE 63           US: MACROECONOMIC INDICATORS    127

TABLE 64           US: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE, 2021–2029 (USD MILLION)     127

TABLE 65           US: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION)    128

TABLE 66           US: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE, 2021–2029 (USD MILLION)          128

TABLE 67           US: TRANSDERMAL PATCHES MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          129

TABLE 68           US: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY, BY TYPE, 2021–2029 (USD MILLION)  129

TABLE 69           US: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 130

TABLE 70           US: TRANSDERMAL PATCHES MARKET, BY END USER, 2021–2029 (USD MILLION)     130

11.2.3    CANADA            130

11.2.3.1 Rising funding for transdermal drug delivery research to drive market     130

TABLE 71           CANADA: MACROECONOMIC INDICATORS       131

TABLE 72           CANADA: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE, 2021–2029 (USD MILLION)          131

TABLE 73           CANADA: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION) 131

TABLE 74           CANADA: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)          132

TABLE 75           CANADA: TRANSDERMAL PATCHES MARKET, BY APPLICATION,  2021–2029 (USD MILLION)        132

TABLE 76           CANADA: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY,  BY TYPE, 2021–2029 (USD MILLION)             133

TABLE 77           CANADA: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 133

TABLE 78           CANADA: TRANSDERMAL PATCHES MARKET, BY END USER, 2021–2029 (USD MILLION)          133

11.3       EUROPE             134

11.3.1    IMPACT OF RECESSION ON EUROPEAN TRANSDERMAL  PATCHES MARKET            134

TABLE 79           EUROPE: TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)          135

TABLE 80           EUROPE: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE, 2021–2029 (USD MILLION)          135

TABLE 81           EUROPE: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION) 136

TABLE 82           EUROPE: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)          136

TABLE 83           EUROPE: TRANSDERMAL PATCHES MARKET, BY APPLICATION,  2021–2029 (USD MILLION)        137

TABLE 84           EUROPE: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY,  BY TYPE, 2021–2029 (USD MILLION)             137

TABLE 85           EUROPE: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 138

TABLE 86           EUROPE: TRANSDERMAL PATCHES MARKET, BY END USER, 2021–2029 (USD MILLION)          138

11.3.2    GERMANY         138

11.3.2.1 Favorable government policies to aid market growth    138

TABLE 87           GERMANY: MACROECONOMIC INDICATORS     139

TABLE 88           GERMANY: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE,  2021–2029 (USD MILLION)          139

TABLE 89           GERMANY: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION) 140

TABLE 90           GERMANY: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)          140

TABLE 91           GERMANY: TRANSDERMAL PATCHES MARKET, BY APPLICATION,  2021–2029 (USD MILLION)        141

TABLE 92           GERMANY: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY, BY TYPE, 2021–2029 (USD MILLION)  141

TABLE 93           GERMANY: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 142

TABLE 94           GERMANY: TRANSDERMAL PATCHES MARKET, BY END USER, 2021–2029 (USD MILLION)          142

11.3.3    UK         142

11.3.3.1 Increasing funding for R&D of innovative transdermal technologies to drive market   142

TABLE 95           UK: MACROECONOMIC INDICATORS    143

TABLE 96           UK: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE, 2021–2029 (USD MILLION)     143

TABLE 97           UK: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION)    143

TABLE 98           UK: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE, 2021–2029 (USD MILLION)          144

TABLE 99           UK: TRANSDERMAL PATCHES MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          144

TABLE 100         UK: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY, BY TYPE, 2021–2029 (USD MILLION)  144

TABLE 101         UK: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 145

TABLE 102         UK: TRANSDERMAL PATCHES MARKET, BY END USER, 2021–2029 (USD MILLION)     145

11.3.4    FRANCE             145

11.3.4.1 Development of transdermal drug delivery systems by local players to support market growth     145

TABLE 103         FRANCE: MACROECONOMIC INDICATORS        146

TABLE 104         FRANCE: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE, 2021–2029 (USD MILLION)          146

TABLE 105         FRANCE: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION) 147

TABLE 106         FRANCE: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)          147

TABLE 107        FRANCE: TRANSDERMAL PATCHES MARKET, BY APPLICATION,  2021–2029 (USD MILLION)          148

TABLE 108         FRANCE: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY,  BY TYPE, 2021–2029 (USD MILLION)             148

TABLE 109         FRANCE: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 149

TABLE 110         FRANCE: TRANSDERMAL PATCHES MARKET, BY END USER, 2021–2029 (USD MILLION)          149

11.3.5    ITALY   149

11.3.5.1 High burden of lung cancer to propel market 149

TABLE 111         ITALY: MACROECONOMIC INDICATORS            150

TABLE 112         ITALY: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE, 2021–2029 (USD MILLION)          150

TABLE 113         ITALY: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION) 150

TABLE 114        ITALY: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE, 2021–2029 (USD MILLION)          151

TABLE 115         ITALY: TRANSDERMAL PATCHES MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          151

TABLE 116         ITALY: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY,  BY TYPE, 2021–2029 (USD MILLION)             151

TABLE 117         ITALY: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 152

TABLE 118         ITALY: TRANSDERMAL PATCHES MARKET, BY END USER, 2021–2029 (USD MILLION)     152

11.3.6    SPAIN   152

11.3.6.1 Growing demand for self-care and personalized medicine  to drive market              152

TABLE 119         SPAIN: MACROECONOMIC INDICATORS            153

TABLE 120         SPAIN: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE, 2021–2029 (USD MILLION)          153

TABLE 121         SPAIN: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION) 153

TABLE 122        SPAIN: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)          154

TABLE 123         SPAIN: TRANSDERMAL PATCHES MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          154

TABLE 124         SPAIN: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY,  BY TYPE, 2021–2029 (USD MILLION)             155

TABLE 125         SPAIN: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 155

TABLE 126         SPAIN: TRANSDERMAL PATCHES MARKET, BY END USER, 2021–2029 (USD MILLION)     155

11.3.7    REST OF EUROPE           156

TABLE 127         REST OF EUROPE: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE,  2021–2029 (USD MILLION)          156

TABLE 128         REST OF EUROPE: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE, 2021–2029 (USD MILLION) 156

TABLE 129         REST OF EUROPE: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)     157

TABLE 130         REST OF EUROPE: TRANSDERMAL PATCHES MARKET, BY APPLICATION,  2021–2029 (USD MILLION)        157

TABLE 131         REST OF EUROPE: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY, BY TYPE, 2021–2029 (USD MILLION)              158

TABLE 132         REST OF EUROPE: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL  2021–2029 (USD MILLION)  158

TABLE 133         REST OF EUROPE: TRANSDERMAL PATCHES MARKET, BY END USER,  2021–2029 (USD MILLION)          158

11.4       ASIA PACIFIC    159

11.4.1    IMPACT OF RECESSION ON ASIA PACIFIC TRANSDERMAL  PATCHES MARKET            159

FIGURE 37         ASIA PACIFIC: TRANSDERMAL PATCHES MARKET SNAPSHOT              160

TABLE 134         ASIA PACIFIC: TRANSDERMAL PATCHES MARKET, BY COUNTRY,  2021–2029 (USD MILLION) 161

TABLE 135         ASIA PACIFIC: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE,  2021–2029 (USD MILLION)          161

TABLE 136         ASIA PACIFIC: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION) 162

TABLE 137         ASIA PACIFIC: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)     162

TABLE 138         ASIA PACIFIC: TRANSDERMAL PATCHES MARKET, BY APPLICATION,  2021–2029 (USD MILLION)        163

TABLE 139         ASIA PACIFIC: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY, BY TYPE, 2021–2029 (USD MILLION)              163

TABLE 140         ASIA PACIFIC: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 164

TABLE 141         ASIA PACIFIC: TRANSDERMAL PATCHES MARKET, BY END USER,  2021–2029 (USD MILLION)          164

11.4.2    CHINA  164

11.4.2.1 Large diabetic population to drive market      164

TABLE 142         CHINA: MACROECONOMIC INDICATORS           165

TABLE 143         CHINA: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE, 2021–2029 (USD MILLION)          165

TABLE 144         CHINA: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION) 166

TABLE 145         CHINA: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)          166

TABLE 146         CHINA: TRANSDERMAL PATCHES MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          167

TABLE 147         CHINA: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY,  BY TYPE, 2021–2029 (USD MILLION)             167

TABLE 148         CHINA: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 167

TABLE 149         CHINA: TRANSDERMAL PATCHES MARKET, BY END USER, 2021–2029 (USD MILLION)          168

11.4.3    JAPAN  168

11.4.3.1 Increasing number of product approvals and growing focus of local players on R&D of transdermal systems to support market growth              168

TABLE 150         JAPAN: MACROECONOMIC INDICATORS            168

TABLE 151         JAPAN: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE, 2021–2029 (USD MILLION)          169

TABLE 152         JAPAN: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION) 169

TABLE 153        JAPAN: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)          170

TABLE 154         JAPAN: TRANSDERMAL PATCHES MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          170

TABLE 155         JAPAN: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY, BY TYPE, 2021–2029 (USD MILLION)  171

TABLE 156         JAPAN: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 171

TABLE 157         JAPAN: TRANSDERMAL PATCHES MARKET, BY END USER, 2021–2029 (USD MILLION)          171

11.4.4    INDIA   172

11.4.4.1 Increasing focus on noninvasive methods of drug delivery to drive market              172

TABLE 158         INDIA: MACROECONOMIC INDICATORS            172

TABLE 159         INDIA: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE, 2021–2029 (USD MILLION)          172

TABLE 160         INDIA: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION) 173

TABLE 161        INDIA: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)          173

TABLE 162         INDIA: TRANSDERMAL PATCHES MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          174

TABLE 163         INDIA: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY,  BY TYPE, 2021–2029 (USD MILLION)             174

TABLE 164         INDIA: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 174

TABLE 165         INDIA: TRANSDERMAL PATCHES MARKET, BY END USER, 2021–2029 (USD MILLION)     175

11.4.5    SOUTH KOREA 175

11.4.5.1 Rising healthcare spending and increasing government initiatives to propel market              175

TABLE 166         SOUTH KOREA: MACROECONOMIC INDICATORS          175

TABLE 167         SOUTH KOREA: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE,  2021–2029 (USD MILLION)          176

TABLE 168         SOUTH KOREA: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION) 176

TABLE 169         SOUTH KOREA: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)     177

TABLE 170         SOUTH KOREA: TRANSDERMAL PATCHES MARKET, BY APPLICATION,  2021–2029 (USD MILLION)        177

TABLE 171         SOUTH KOREA: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY, BY TYPE, 2021–2029 (USD MILLION)              178

TABLE 172         SOUTH KOREA: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 178

TABLE 173         SOUTH KOREA: TRANSDERMAL PATCHES MARKET, BY END USER,  2021–2029 (USD MILLION)          178

11.4.6    AUSTRALIA       179

11.4.6.1 Increasing number of smokers to drive market             179

TABLE 174         AUSTRALIA: MACROECONOMIC INDICATORS  179

TABLE 175         AUSTRALIA: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE,  2021–2029 (USD MILLION)          179

TABLE 176         AUSTRALIA: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION) 180

TABLE 177         AUSTRALIA: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)          180

TABLE 178         AUSTRALIA: TRANSDERMAL PATCHES MARKET, BY APPLICATION,  2021–2029 (USD MILLION)        181

TABLE 179         AUSTRALIA: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY, BY TYPE, 2021–2029 (USD MILLION)              181

TABLE 180         AUSTRALIA: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 182

TABLE 181         AUSTRALIA: TRANSDERMAL PATCHES MARKET, BY END USER,  2021–2029 (USD MILLION)          182

11.4.7    REST OF ASIA PACIFIC  182

TABLE 182         REST OF ASIA PACIFIC: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE,  2021–2029 (USD MILLION)          183

TABLE 183         REST OF ASIA PACIFIC: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE, 2021–2029 (USD MILLION) 183

TABLE 184         REST OF ASIA PACIFIC: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)     184

TABLE 185         REST OF ASIA PACIFIC: TRANSDERMAL PATCHES MARKET, BY APPLICATION,  2021–2029 (USD MILLION)        184

TABLE 186         REST OF ASIA PACIFIC: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY, BY TYPE, 2021–2029 (USD MILLION)              185

TABLE 187         REST OF ASIA PACIFIC: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD MILLION)    185

TABLE 188         REST OF ASIA PACIFIC: TRANSDERMAL PATCHES MARKET, BY END USER,  2021–2029 (USD MILLION) 185

11.5       LATIN AMERICA             186

11.5.1    IMPACT OF RECESSION ON TRANSDERMAL PATCHES MARKET  IN LATIN AMERICA             186

TABLE 189         LATIN AMERICA: TRANSDERMAL PATCHES MARKET, BY COUNTRY,  2021–2029 (USD MILLION) 186

TABLE 190         LATIN AMERICA: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE,  2021–2029 (USD MILLION)          187

TABLE 191         LATIN AMERICA: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION)           187

TABLE 192         LATIN AMERICA: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)     188

TABLE 193         LATIN AMERICA: TRANSDERMAL PATCHES MARKET, BY APPLICATION,  2021–2029 (USD MILLION)        188

TABLE 194         LATIN AMERICA: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY, BY TYPE, 2021–2029 (USD MILLION)              189

TABLE 195         LATIN AMERICA: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 189

TABLE 196         LATIN AMERICA: TRANSDERMAL PATCHES MARKET, BY END USER,  2021–2029 (USD MILLION)          189

11.5.2    BRAZIL 190

11.5.2.1 High prevalence of diabetes to propel market 190

TABLE 197         BRAZIL: KEY MACROINDICATORS          190

TABLE 198         BRAZIL: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE, 2021–2029 (USD MILLION)          190

TABLE 199         BRAZIL: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION) 191

TABLE 200         BRAZIL: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)          191

TABLE 201         BRAZIL: TRANSDERMAL PATCHES MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          191

TABLE 202         BRAZIL: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY,  BY TYPE, 2021–2029 (USD MILLION)             192

TABLE 203         BRAZIL: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 192

TABLE 204         BRAZIL: TRANSDERMAL PATCHES MARKET, BY END USER, 2021–2029 (USD MILLION)          192

11.5.3    MEXICO             193

11.5.3.1 Government investments to drive transdermal drug delivery production  193

TABLE 205         MEXICO: KEY MACROINDICATORS        193

TABLE 206         MEXICO: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE, 2021–2029 (USD MILLION)          193

TABLE 207         MEXICO: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE,  2021–2029 (USD MILLION) 194

TABLE 208         MEXICO: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)          194

TABLE 209        MEXICO: TRANSDERMAL PATCHES MARKET, BY APPLICATION,  2021–2029 (USD MILLION)          195

TABLE 210         MEXICO: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY,  BY TYPE, 2021–2029 (USD MILLION)             195

TABLE 211         MEXICO: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL,  2021–2029 (USD MILLION) 196

TABLE 212         MEXICO: TRANSDERMAL PATCHES MARKET, BY END USER, 2021–2029 (USD MILLION)          196

11.5.4    REST OF LATIN AMERICA          196

TABLE 213         REST OF LATIN AMERICA: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE,  2021–2029 (USD MILLION)     197

TABLE 214         REST OF LATIN AMERICA: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET,  BY TYPE, 2021–2029 (USD MILLION)              197

TABLE 215         REST OF LATIN AMERICA: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)             198

TABLE 216         REST OF LATIN AMERICA: TRANSDERMAL PATCHES MARKET, BY APPLICATION,  2021–2029 (USD MILLION)   198

TABLE 217         REST OF LATIN AMERICA: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY, BY TYPE, 2021–2029 (USD MILLION)              199

TABLE 218         REST OF LATIN AMERICA: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD MILLION)            199

TABLE 219         REST OF LATIN AMERICA: TRANSDERMAL PATCHES MARKET, BY END USER,  2021–2029 (USD MILLION)         199

 

11.6       MIDDLE EAST & AFRICA             200

11.6.1    GOVERNMENT SUPPORT TO BOOST LOCAL PRODUCTION TO OFFER GROWTH OPPORTUNITIES FOR TRANSDERMAL PATCH MANUFACTURERS              200

11.6.2    IMPACT OF RECESSION ON TRANSDERMAL PATCHES MARKET  IN MIDDLE EAST AND AFRICA       200

TABLE 220         MIDDLE EAST & AFRICA: TRANSDERMAL PATCHES MARKET, BY PATCH TYPE,  2021–2029 (USD MILLION)     201

TABLE 221         MIDDLE EAST & AFRICA: DRUG-IN-ADHESIVE TRANSDERMAL PATCHES MARKET, BY TYPE, 2021–2029 (USD MILLION) 201

TABLE 222         MIDDLE EAST & AFRICA: TRANSDERMAL PATCHES MARKET, BY ADHESIVE TYPE,  2021–2029 (USD MILLION)             202

TABLE 223         MIDDLE EAST & AFRICA: TRANSDERMAL PATCHES MARKET, BY APPLICATION,  2021–2029 (USD MILLION)   202

TABLE 224         MIDDLE EAST & AFRICA: TRANSDERMAL PATCHES MARKET FOR HORMONE REPLACEMENT THERAPY, BY TYPE, 2021–2029 (USD MILLION)              203

TABLE 225         MIDDLE EAST & AFRICA: TRANSDERMAL PATCHES MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD MILLION)            203

TABLE 226         MIDDLE EAST & AFRICA: TRANSDERMAL PATCHES MARKET, BY END USER,  2021–2029 (USD MILLION)         203

12          COMPETITIVE LANDSCAPE       204

12.1       INTRODUCTION            204

TABLE 227         KEY DEVELOPMENTS IN TRANSDERMAL PATCHES MARKET  (JANUARY 2020–OCTOBER 2023)             204

12.2       REVENUE ANALYSIS OF KEY MARKET PLAYERS 205

FIGURE 38         REVENUE ANALYSIS OF KEY PLAYERS IN TRANSDERMAL PATCHES MARKET        205

12.3       MARKET SHARE ANALYSIS         206

FIGURE 39         TRANSDERMAL PATCHES MARKET SHARE, BY KEY PLAYER, 2022      206

12.4       COMPANY FOOTPRINT 207

12.4.1    FOOTPRINT OF COMPANIES IN TRANSDERMAL PATCHES MARKET              207

12.4.2    PATCH TYPE FOOTPRINT          208

12.4.3    ADHESIVE TYPE FOOTPRINT    209

12.4.4    APPLICATION FOOTPRINT       210

12.4.5    DISTRIBUTION CHANNEL FOOTPRINT 211

12.4.6    END-USER FOOTPRINT 212

12.4.7    REGIONAL FOOTPRINT             213

12.5       TRANSDERMAL PATCHES MARKET: R&D EXPENDITURE            214

FIGURE 40         R&D EXPENDITURE OF KEY PLAYERS IN TRANSDERMAL PATCHES MARKET (2021 VS. 2022)          214

12.6       COMPANY EVALUATION MATRIX          215

12.6.1    STARS  215

12.6.2    EMERGING LEADERS    215

12.6.3    PERVASIVE PLAYERS     215

12.6.4    PARTICIPANTS 215

FIGURE 41         TRANSDERMAL PATCHES MARKET: COMPANY EVALUATION MATRIX, 2022    216

12.7       SME/STARTUP EVALUATION MATRIX   216

12.7.1    PROGRESSIVE COMPANIES       216

12.7.2    STARTING BLOCKS       216

12.7.3    RESPONSIVE COMPANIES          217

12.7.4    DYNAMIC COMPANIES 217

FIGURE 42         TRANSDERMAL PATCHES MARKET: SME/STARTUP EVALUATION MATRIX  217

12.7.5    COMPETITIVE BENCHMARKING            218

TABLE 228         TRANSDERMAL PATCHES MARKET: DETAILED LIST OF KEY STARTUP/SMES             218

12.8       COMPETITIVE SITUATION AND TRENDS           218

12.8.1    PRODUCT LAUNCHES  218

TABLE 229         TRANSDERMAL PATCHES MARKET: PRODUCT LAUNCHES,  JANUARY 2020–OCTOBER 2023  218

12.8.2    DEALS  219

TABLE 230         TRANSDERMAL PATCHES MARKET: DEALS, JANUARY 2020–OCTOBER 2023 219

12.8.3    OTHER DEVELOPMENTS           220

TABLE 231         TRANSDERMAL PATCHES MARKET: OTHER DEVELOPMENTS,  JANUARY 2020–OCTOBER 2023  220

13          COMPANY PROFILES    221

(Business overview, Products offered, Recent developments & MnM View)*

13.1       KEY PLAYERS   221

13.1.1    HISAMITSU PHARMACEUTICAL CO., INC.           221

TABLE 232         HISAMITSU PHARMACEUTICAL CO., INC.: BUSINESS OVERVIEW        221

FIGURE 43         HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2022)          222

13.1.2    VIATRIS INC.     225

TABLE 233         VIATRIS INC.: BUSINESS OVERVIEW       225

FIGURE 44         VIATRIS INC.: COMPANY SNAPSHOT (2022)       226

13.1.3    NOVARTIS AG   229

TABLE 234         NOVARTIS AG: BUSINESS OVERVIEW    229

FIGURE 45         NOVARTIS AG: COMPANY SNAPSHOT (2022)     230

13.1.4    BOEHRINGER INGELHEIM INTERNATIONAL GMBH       232

TABLE 235         BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW        232

FIGURE 46         BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022)          233

13.1.5    JOHNSON & JOHNSON  235

TABLE 236         JOHNSON & JOHNSON: BUSINESS OVERVIEW    235

FIGURE 47         JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)    236

13.1.6    UCB S.A.             238

TABLE 237         UCB S.A.: BUSINESS OVERVIEW 238

FIGURE 48         UCB S.A.: COMPANY SNAPSHOT (2022) 238

13.1.7    ENDO INTERNATIONAL PLC     240

TABLE 238         ENDO INTERNATIONAL PLC: BUSINESS OVERVIEW       240

FIGURE 49         ENDO INTERNATIONAL PLC: COMPANY SNAPSHOT (2022)              240

13.1.8    LUYE PHARMA GROUP 242

TABLE 239         LUYE PHARMA GROUP: BUSINESS OVERVIEW   242

FIGURE 50         LUYE PHARMA GROUP: COMPANY SNAPSHOT (2022)    242

13.1.9    ABBVIE INC.      244

TABLE 240         ABBVIE INC.: BUSINESS OVERVIEW        244

FIGURE 51         ABBVIE INC.: COMPANY SNAPSHOT (2022)        245

13.1.10  NITTO DENKO CORPORATION 247

TABLE 241         NITTO DENKO CORPORATION: BUSINESS OVERVIEW  247

FIGURE 52         NITTO DENKO CORPORATION: COMPANY SNAPSHOT (2022)              247

13.1.11  CIPLA INC.         249

TABLE 242         CIPLA INC.: BUSINESS OVERVIEW          249

FIGURE 53         CIPLA INC.: COMPANY SNAPSHOT (2022)           249

13.1.12  TEVA PHARMACEUTICAL INDUSTRIES LTD.     251

TABLE 243         TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW        251

FIGURE 54         TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2022)          251

13.1.13  AGILE THERAPEUTICS 253

TABLE 244         AGILE THERAPEUTICS: BUSINESS OVERVIEW   253

FIGURE 55         AGILE THERAPEUTICS: COMPANY SNAPSHOT (2022)    253

13.1.14  BAYER AG          255

TABLE 245         BAYER AG: BUSINESS OVERVIEW           255

FIGURE 56         BAYER AG: COMPANY SNAPSHOT (2022)            256

13.1.15  AMNEAL PHARMACEUTICALS LLC        258

TABLE 246         AMNEAL PHARMACEUTICALS LLC: BUSINESS OVERVIEW              258

FIGURE 57         AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT (2022)   258

13.1.16  HIKMA PHARMACEUTICALS PLC           260

TABLE 247         HIKMA PHARMACEUTICALS PLC: BUSINESS OVERVIEW 260

FIGURE 58         HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2022)              260

*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.

13.2       OTHER PLAYERS           262

13.2.1    ALVOGEN GROUP INC. 262

TABLE 248         ALVOGEN GROUP INC.: COMPANY OVERVIEW 262

13.2.2    SPARSHA PHARMA INTERNATIONAL PVT. LTD. 262

TABLE 249         SPARSHA PHARMA INTERNATIONAL PVT. LTD.: COMPANY OVERVIEW        262

13.2.3    IONTOPATCH  263

TABLE 250         IONTOPATCH: COMPANY OVERVIEW   263

13.2.4    MEDHERANT LIMITED 263

TABLE 251         MEDHERANT LIMITED: COMPANY OVERVIEW  263

13.2.5    ADHEXPHARMA             264

TABLE 252         ADHEXPHARMA: COMPANY OVERVIEW             264

13.2.6    EVERNOW         264

TABLE 253         EVERNOW: COMPANY OVERVIEW          264

13.2.7    LEAD CHEMICAL CO., LTD.       265

TABLE 254         LEAD CHEMICAL CO., LTD.: COMPANY OVERVIEW        265

13.2.8    PURDUE PHARMA L.P.  265

TABLE 255         PURDUE PHARMA L.P.: COMPANY OVERVIEW  265

13.2.9    MUNDIPHARMA INTERNATIONAL         266

TABLE 256         MUNDIPHARMA INTERNATIONAL: COMPANY OVERVIEW              266

13.3       COMPANIES PROVIDING ADHESIVES FOR  TRANSDERMAL PATCHES              267

13.3.1    WACKER CHEMIE AG    267

13.3.1.1 Business overview 267

TABLE 257         WACKER CHEMIE AG: BUSINESS OVERVIEW      267

FIGURE 59         WACKER CHEMIE AG: COMPANY SNAPSHOT (2022)       268

13.3.1.2 Products offered  268

13.3.2    ELKEM ASA       269

13.3.2.1 Business overview 269

TABLE 258         ELKEM ASA: BUSINESS OVERVIEW         269

FIGURE 60         ELKEM ASA: COMPANY SNAPSHOT (2022)          270

13.3.2.2 Products offered  270

13.3.3    DUPONT DE NEMOURS, INC.     271

13.3.3.1 Business overview 271

TABLE 259         DUPONT DE NEMOURS, INC.: BUSINESS OVERVIEW      271

FIGURE 61         DUPONT DE NEMOURS, INC.: COMPANY SNAPSHOT (2022)              272

13.3.3.2 Products offered  272

13.3.4    KATECHO, LLC 273

TABLE 260         KATECHO, LLC: COMPANY OVERVIEW 273

13.3.5    POLYMER SCIENCE, INC.            273

TABLE 261         POLYMER SCIENCE, INC.: COMPANY OVERVIEW            273

14          APPENDIX         274

14.1       DISCUSSION GUIDE      274

14.2       KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL             278

14.3       CUSTOMIZATION OPTIONS      280

14.4       RELATED REPORTS       280

14.5       AUTHOR DETAILS         281